Results 1 to 10 of about 1,319 (96)
Noncirrhotic Portal Hypertension due to Nodular Regenerative Hyperplasia Treated with Surgical Portacaval Shunt [PDF]
Case Reports in Medicine, 2012 Nodular regenerative hyperplasia (NRH) is an uncommon condition, but an important cause of noncirrhotic intrahepatic portal hypertension (NCIPH), characterized by micronodules of regenerative hepatocytes throughout the liver without intervening fibrous ...
Lisa M. Louwers +5 more
doaj +4 more sources
A modified microsurgical model for end-to-side selective portacaval shunt in the rat: intraoperative microcirculatory investigations [PDF]
Acta Cirúrgica Brasileira, 2013 PURPOSE: To investigate the intraoperative microcirculatory changes of the affected organs (small bowel, liver and kidney) during the making of a modified selective portacaval (PC) shunt.
Zoltan Klarik +5 more
doaj +5 more sources
Journal of Internal Medicine, Volume 294, Issue 3, Page 281-294, September 2023., 2023 Abstract The prevalence of cognitive dysfunction, dementia, and neurodegenerative disorders such as Alzheimer's disease (AD) is increasing in parallel with an aging population. Distinct types of chronic stress are thought to be instrumental in the development of cognitive impairment in central nervous system (CNS) disorders where cognitive impairment ...
Torbjörn Bäckström +4 more
wiley +1 more source
Disease Markers, Volume 2023, Issue 1, 2023., 2023 Objective. Patients with cirrhosis and splenomegaly often have coagulation dysfunction which affects treatment and prognosis. This study explores the status, grading, and treatment strategies of coagulation dysfunction in patients with liver cirrhosis and splenomegaly. Methods.
Yunfu Lv +7 more
wiley +1 more source
Case Reports in Hepatology, Volume 2023, Issue 1, 2023., 2023 Hepatic encephalopathy (HE) is a frequent and serious complication of chronic liver disease. The mechanism of hepatic encephalopathy is not entirely clear. Hepatic encephalopathy is defined as brain dysfunction caused by liver insufficiency and/or portal‐systemic blood shunting.
Fady Salama +4 more
wiley +1 more source
Portal Hypertension &Cirrhosis, Volume 1, Issue 2, Page 133-144, September 2022., 2022 Prognostic tools for survival prediction and risk stratification after transjugular intrahepatic portosystemic shunt placement. Abstract Patient prognosis after transjugular intrahepatic portosystemic shunt (TIPS) placement is relatively poor and highly heterogeneous; therefore, a prognostic scoring system is essential for survival prediction and risk ...
Chongtu Yang, Bin Xiong
wiley +1 more source
Hepatology Communications, Volume 6, Issue 7, Page 1803-1812, July 2022., 2022 Patients with chronic, obliterative portal vein thrombosis may be converted to liver transplantation candidacy following portal vein recanalization‐transjugular intrahepatic portosystemic shunt (PVR‐TIPS). Long‐term survival outcomes of patients with chronic, obliterative portal vein thrombosis who undergo transplantation following PVR‐TIPS are similar
Abhinav Talwar +15 more
wiley +1 more source
The Journal of Clinical Pharmacology, Volume 62, Issue 6, Page 812-822, June 2022., 2022 Abstract Acalabrutinib received approval for the treatment of adult patients with mantle cell lymphoma who received at least 1 prior therapy and adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. This study investigated the impact of hepatic impairment (HI) on acalabrutinib pharmacokinetics (PK) and safety at a single 50‐mg
Yan Xu +13 more
wiley +1 more source
Late Bleeding Episodes Following Intestinal Transplantation
JPGN Reports, Volume 3, Issue 2, May 2022., 2022 Ectopic varices have been reported in 5% of children presenting with variceal bleeding and are defined as portosystemic venous collaterals occurring anywhere in the abdomen except in the cardioesophageal region. The liver‐intestinal transplant or isolated liver‐intestinal transplant patient presenting several years post‐transplant with ectopic variceal
Harveen Singh +6 more
wiley +1 more source
Clinical Pharmacology in Drug Development, Volume 10, Issue 7, Page 707-717, July 2021., 2021 Abstract This phase I open‐label trial (NCT03627754) assessed glasdegib pharmacokinetics and safety in otherwise healthy participants with moderate (Child‐Pugh B) or severe (Child‐Pugh C) hepatic impairment. Participants with hepatic impairment and age/weight‐matched controls with normal hepatic function received a single oral 100‐mg glasdegib dose ...
Joanna C. Masters +4 more
wiley +1 more source